Induction of PD-L1 on monocytes: A new mechanism by which IVIg inhibits mixed lymphocyte reactions

Immunobiology

Volumn 219, Issue 9, 2014, Pages 687-694

  Padet, Lauriane ^a,b   Loubaki, Lionel ^a   Bazin, Renée ^a,b  

^a Department of Research and Development Héma Québec ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Intravenous immunoglobulin; Mixed lymphocyte reaction; PD L1; T cell activation

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOMODULATORY ACTIVITY; IN VITRO STUDY; MIXED LYMPHOCYTE REACTION; MONOCYTE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; BIOSYNTHESIS; DRUG EFFECTS; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIXED LYMPHOCYTE CULTURE;

ANTIGENS, CD274; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IN VITRO TECHNIQUES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84904017104     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.04.001     Document Type: Article

References (59)

1. Al-Chaqmaqchi H., Sadeghi B., Abedi-Valugerdi M., Al-Hashmi S., Fares M., Kuiper R., Lundahl J., Hassan M., Moshfegh A. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS ONE 2013, 8:e60367.
2. Alpdogan O., van den Brink M.R. Immune tolerance and transplantation. Semin. Oncol. 2012, 39:629-642.
3. Antin J.H., Weisdorf D., Neuberg D., Nicklow R., Clouthier S., Lee S.J., Alyea E., McGarigle C., Blazar B.R., Sonis S., Soiffer R.J., Ferrara J.L. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002, 100:3479-3482.
4. Arend W.P., Malyak M., Guthridge C.J., Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 1998, 16:27-55.
5. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
6. Blazar B.R., Carreno B.M., Panoskaltsis-Mortari A., Carter L., Iwai Y., Yagita H., Nishimura H., Taylor P.A. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J. Immunol. 2003, 171:1272-1277.
7. Bobrie A., Colombo M., Raposo G., Théry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011, 12:1659-1668.
8. Booth A.J., Grabauskiene S., Wood S.C., Lu G., Burrell B.E., Bishop D.K. IL-6 promotes cardiac graft rejection mediated by CD4+ cells. J. Immunol. 2011, 187:5764-5771.
9. Boros P., Gondolesi G., Bromberg J.S. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl. 2005, 11:1469-1480.
10. Carreno B.M., Bennett F., Chau T.A., Ling V., Luxenberg D., Jussif J., Baroja M.L., Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 2000, 165:1352-1356.
11. Casadei D.H., del C.R.M., Opelz G., Golberg J.C., Argento J.A., Greco G., Guardia O.E., Haas E., Raimondi E.H. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001, 71:53-58.
12. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013, 13:227-242.
13. Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin. Exp. Immunol. 2011, 164(Suppl. 2):16-19.
14. Curtsinger J.M., Mescher M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 2010, 22:333-340.
15. del Rio M.L., Buhler L., Gibbons C., Tian J., Rodriguez-Barbosa J.I. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl. Int. 2008, 21:1015-1028.
16. Dienz O., Rincon M. The effects of IL-6 on CD4T cell responses. Clin. Immunol. 2009, 130:27-33.
17. Dong C., Juedes A.E., Temann U.A., Shresta S., Allison J.P., Ruddle N.H., Flavell R.A. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101.
18. D'Orsogna L.J., Roelen D.L., Doxiadis I.I., Claas F.H. TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition. Immunogenetics 2012, 64:77-85.
19. Dustin M.L., Bivona T.G., Philips M.R. Membranes as messengers in T cell adhesion signaling. Nat. Immunol. 2004, 5:363-372.
20. Eagar T.N., Karandikar N.J., Bluestone J.A., Miller S.D. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur. J. Immunol. 2002, 32:972-981.
21. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
22. Game D.S., Lechler R.I. Pathways of allorecognition: implications for transplantation tolerance. Transpl. Immunol. 2002, 10:101-108.
23. Gregoire-Gauthier J., Durrieu L., Duval A., Fontaine F., Dieng M.M., Bourgey M., Patey-Mariaud de Serre N., Louis I., Haddad E. Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/gammac- mouse model. Bone Marrow Transplant. 2012, 47:439-450.
24. Jordan S.C., Toyoda M., Kahwaji J., Vo A.A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am. J. Transplant. 2011, 11:196-202.
25. Kawada K., Terasaki P.I. Evidence for immunosuppression by high-dose gammaglobulin. Exp. Hematol. 1987, 15:133-136.
26. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., Koulmanda M., Freeman G.J., Sayegh M.H., Sharpe A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006, 203:883-895.
27. Klaesson S., Ringden O., Markling L., Remberger M., Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand. J. Immunol. 1993, 38:477-484.
28. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
29. Liseth K., Sjo M., Paulsen K., Bruserud O., Ersvaer E. Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. Eur. Cytokine Netw. 2010, 21:40-49.
30. Mollee P., Morton A.J., Irving I., Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br. J. Haematol. 2001, 113:217-223.
31. Monks C.R., Freiberg B.A., Kupfer H., Sciaky N., Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998, 395:82-86.
32. Nakagiri T., Inoue M., Minami M., Shintani Y., Okumura M. Immunology mini-review: the basics of T(H)17 and interleukin-6 in transplantation. Transplant. Proc. 2012, 44:1035-1040.
33. Padet L., St-Amour I., Aubin E., Bazin R. Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?. Clin. Exp. Immunol. 2011, 166:352-360.
34. Padet L., Bazin R. IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators. Immunol. Lett. 2013, 150:54-60.
35. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., Linsley P.S., Thompson C.B., Riley J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
36. Peraldi M.N., Akposso K., Haymann J.P., Flahaut A., Marlin C., Rondeau E., Sraer J.D. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996, 62:1670-1673.
37. Reed J.M., Branigan P.J., Bamezai A. Interferon gamma enhances clonal expansion and survival of CD4+ T cells. J. Interferon Cytokine Res. 2008, 28:611-622.
38. Ratanatharathorn V., Ayash L., Lazarus H.M., Fu J., Uberti J.P. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001, 28:121-129.
39. Rovira P., Mascarell L., Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr. Med. Chem. 2000, 7:673-692.
40. Saghafi H., Rahbar K., Nobakht Haghighi A., Qoreishi M., Safdari F. Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation. Nephrourol. Mon. 2012, 4:475-477.
41. Sandner S.E., Clarkson M.R., Salama A.D., Sanchez-Fueyo A., Domenig C., Habicht A., Najafian N., Yagita H., Azuma M., Turka L.A., Sayegh M.H. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 2005, 174:3408-3415.
42. Skansen-Saphir U., Andersson J., Bjork L., Ekberg C., Fehniger T.E., Henter J.I., Andersson U. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand. J. Immunol. 1998, 47:229-235.
43. Socie G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
44. Smith-Garvin J.E., Koretzky G.A., Jordan M.S. T cell activation. Annu. Rev. Immunol. 2009, 27:591-619.
45. Sokos D.R., Berger M., Lazarus H.M. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2002, 8:117-130.
46. Sullivan K.M., Kopecky K.J., Jocom J., Fisher L., Buckner C.D., Meyers J.D., Counts G.W., Bowden R.A., Peterson F.B., Witherspoon R.P., Budinger M.D., Shwartz R.S., Appelbaum F.R., Clift R.A., Hansen J.A., Sanders J.E., Donnall Thomas E., Storb R. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 1990, 323:705-712.
47. Sullivan K.M. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin. Exp. Immunol. 1996, 104(Suppl 1):43-48.
48. Tanaka K., Albin M.J., Yuan X., Yamaura K., Habicht A., Murayama T., Grimm M., Waaga A.M., Ueno T., Padera R.F., Yagita H., Azuma M., Shin T., Blazar B.R., Rothstein D.M., Sayegh M.H., Najafian N. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J. Immunol. 2007, 179:5204-5210.
49. Toungouz M., Denys C., Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996, 62:1292-1296.
50. Toyoda M., Zhang X.M., Petrosian A., Wachs K., Moudgil A., Jordan S.C. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl. Immunol. 1994, 2:337-341.
51. Toyoda M., Pao A., Petrosian A., Jordan S.C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am. J. Transplant. 2003, 3:156-166.
52. Trepanier P., Bazin R. Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation. Blood 2012, 120:2769-2770.
53. Trinath J., Hegde P., Sharma M., Maddur M., Rabin M., Vallat J.M., Magy L., Balaji K.N., Kaveri S.V., Bayry J. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 2013, 122:1419-1427.
54. Tyan D.B., Li V.A., Czer L., Trento A., Jordan S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994, 57:553-562.
55. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
56. Via C.S., Rus V., Nguyen P., Linsley P., Gause W.C. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J. Immunol. 1996, 157:4258-4267.
57. Wiseman A.C., Pietra B.A., Kelly B.P., Rayat G.R., Rizeq M., Gill R.G. Donor IFN-gamma receptors are critical for acute CD4(+) T cell-mediated cardiac allograft rejection. J. Immunol. 2001, 167:5457-5463.
58. Wojciechowski D., Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Tranplant. 2012, 17:640-647.
59. Yarkoni S., Prigozhina T.B., Slavin S., Askenasy N. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol. Blood Marrow Transplant. 2012, 18:523-535.